Kim et al., showed that a dual PI3K/mTOR inhibitor, named CMG002, in combination with sorafenib significantly inhibits HCC cells proliferation and metastasis in in vitro and in vivo experiments. The gene discussed is MTOR; the disease is hepatocellular carcinoma.